`Drugs.com
`
`Eylea FDA ApprovalHistory
`FDA Approved: Yes (First approved November 18, 2011)
`Brand name: Eylea
`Generic name:aflibercept
`Dosage form: Injection
`Company: Regeneron Pharmaceuticals, Inc.
`Treatment for: Macular Degeneration, Macular Edema, Diabetic Retinopathy
`
`Eylea (aflibercept) is a VEGFinhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following
`
`Development Timeline for Eylea
`
`Aug 13,2019
`
`Approval FDA Approves Eylea (aflibercept) Injection Prefilled Syringe
`
`May 13,2019
`
`Approval FDA Approves Eylea (aflibercept) Injection for Diabetic Retinopathy
`
`
`
`Approval FDA Approves New Eylea (aflibercept) Injection Dosing Schedule in Wet Age-Related Macular Degeneration
`Aug 17, 2018
`
`Mar 25,2015
`Approval
`_FDA Approves Eylea (aflibercept) for Diabetic Retinopathy in Patients with Diabetic Macular Edema
`
`Approval Eylea (aflibercept) Injection Receives FDA Approval for the Treatment ofDiabetic Macular Edema
`Jul 29, 2014
`
`Nov 18, 2011
`Approval FDA Approves Eylea forWetAge-Related Macular Degeneration
`
`Aug 17,2011
`
`Regeneron Announces ReviewofBiologics License Application for Eylea (aflibercept injection) Extended by Three Months by FDA
`
`Jun 17,2011
`
`Regeneron Announces Eylea (afliberceptophthalmic solution) Receives Unanimous Recommendation for Approval forTreatment ofWetAMD from FDAAdvisory Committee
`
`Further information
`Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
`
`Exhibit 2181
`Page 01 of 01
`
`
`
`Mylan v. Regeneron
`IPR2021-00881
`U.S. Pat. 9,254,338
`Exhibit 2181
`
`Exhibit 2181
`Page 01 of 01
`
`